The OIG report is evidence that the Orphan Drug Act is not working as intended. OIG looked at the 20 drugs in Part B and Part D with the highest expenditures and found that 22 of these 40 were orphan drugs. Interestingly, 15 of those 22 orphan drugs also had approved non-orphan indications, making them partial orphan drugs (drugs approved to treat both rare and common diseases).
Pharmaceutical Care
Management Association
325 7th Street, NW
Washington, DC 20004
Main: 202.756.5700
©2024 PCMA. All Rights Reserved.